Carbon Tetrachloride

Carbon Tetrachloride

SCHEMBL967417

CC#N.ClC(Cl)(Cl)Cl

nearest known ligand 0.00

Full drug profile on Sugi Atlas →

⚠ Novel chemotype — no close known analogue (best Tanimoto < 0.3). Unexplored chemical space relative to ChEMBL.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 84 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20240158367-A1 TRICYCLIC COMPOUND AS HIF2-ALPHA INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF SHANGHAI JEMINCARE PHARMACEUTICALS CO., LTD (CN) 2024-05-16 US disclosed
EP-4299570-A1 TRICYCLIC COMPOUND AS HIF2A INHIBITOR, PREPARATION METHOD THEREFOR AND APPLICATION THEREOF Shanghai Jemincare Pharmaceuticals Co., Ltd. (CN) 2024-01-03 EP disclosed
CN-116724035-A Tri-fused ring compounds as HIF2 alpha inhibitors, and preparation method and application thereof 上海济煜医药科技有限公司 2023-09-08 CN disclosed
US-11319300-B2 Polyfluoro-substituted aromatic heterocyclic derivative, pharmaceutical composition containing same, and applications thereof GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) 2022-05-03 US disclosed
CN-114206864-A Quinazoline-2, 4-dione derivatives as PARP inhibitors 苏州四体康宸医药科技有限公司 2022-03-18 CN disclosed
CN-108872106-B Method for measuring trace sulfite in water body 电子科技大学 2021-03-19 CN disclosed
US-20200165229-A1 POLYFLUORO-SUBSTITUTED AROMATIC HETEROCYCLIC DERIVATIVE, PHARMACEUTICAL COMPOSITION CONTAINING SAME, AND APPLICATIONS THEREOF GUANGZHOU LIXIN PHARMACEUTICAL CO., LTD. (CN) 2020-05-28 US disclosed
US-10577359-B2 Preparation of 2′-fluoro-2′-alkyl-substituted or other optionally substituted ribofuranosyl pyrimidines and purines and their derivatives GILEAD PHARMASSET LLC (US) 2020-03-03 US disclosed
EP-1809301-B1 2-FLUORO-2-ALKYL-SUBSTITUTED D-RIBONOLACTONE INTERMEDIATES GILEAD PHARMASSET LLC (US) 2019-11-06 EP disclosed
CN-110337428-A The method for being used to prepare fluoro-alkyl nitrile and corresponding fluoro-alkyl tetrazolium 拜耳作物科学股份公司 2019-10-15 CN disclosed
EP-0497673-B1 Medical material, method for production thereof, and medical apparatus TERUMO CORP (JP) 1997-03-26 EP disclosed
US-5599922-A INHIBITOR TO SNAKE VENON PHOSPHODIESTERASE LYNX THERAPEUTICS, INC. (US) 1997-02-04 US disclosed
EP-0754242-A1 OLIGONUCLEOTIDE N3'$m(7)P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES LYNX THERAPEUTICS, INC. (US) 1997-01-22 EP disclosed
EP-0753315-A2 Medical material, method for production thereof, and medical apparatus TERUMO KABUSHIKI KAISHA (JP) 1997-01-15 EP disclosed
US-5591607-A Oligonucleotide N3→P5' phosphoramidates: triplex DNA formation LYNX THERAPEUTICS, INC. (US) 1997-01-07 US disclosed
US-5489303-A BOUND TO THE SURFACE OF POLYMERIC SUBSTRATE VIA A COPOLYMER CONTAINING EPOXY, CARBOXY, CARBOXYESTER, ALCOHOL AND ALDEHYDE REACTIVE GROUPS TERUMO KABUSHIKI KAISHA (JP) 1996-02-06 US disclosed
WO-1995025814-A1 OLIGONUCLEOTIDE N3'→P5' PHOSPHORAMIDATES: SYNTHESIS AND COMPOUNDS; HYBRIDIZATION AND NUCLEASE RESISTANCE PROPERTIES LYNX THERAPEUTICS, INC. (US) 1995-09-28 WO disclosed
EP-0509753-A1 Semi-synthetic immunosuppressive macrolides MERCK & CO. INC. (US) 1992-10-21 EP disclosed
US-5147877-A Autoimmune and skin disorders, organ transplant MERCK & CO. INC. (US) 1992-09-15 US disclosed
EP-0497673-A1 Medical material, method for production thereof, and medical apparatus TERUMO KABUSHIKI KAISHA (JP) 1992-08-05 EP disclosed